EGFR and non-small cell lung carcinoma: In a retrospective analysis that included 58 patients with NSCLC treated with anti-PD-1/PD-L1 therapies, EGFR-mutant or ALK-positive patients showed a statistically significant shorter PFS and borderline significant lower ORR compared with EGFR wild-type and ALK-negative/unknown patients [42].